Holoclara
Holoclara is the first company to create orally available, worm-derived therapies that provide relief to millions of people living with allergic and autoimmune disease.
Challenge
Holoclara, a biotech company pioneering worm-derived therapeutics for autoimmune diseases, needed a communications strategy that would introduce its novel approach, establish credibility, and attract investors and industry attention
Approach
Thermal developed and executed a strategic PR campaign to position Holoclara as a category-defining company in immune therapeutics. Our approach included:
-
- Defining and sharpening Holoclara’s narrative, ensuring its science was framed as both rigorous and revolutionary.
- Driving exclusive media placements that shaped public perception—Thermal secured a Fortune exclusive for Holoclara’s $16M Series A, placing the company’s novel platform in front of investors and biotech leaders.
- Positioning Holoclara’s leadership as scientific pioneers, securing a Forbes feature on the CEO’s vision and the broader implications of worm-derived therapeutics.
- Generating momentum around clinical progress, landing coverage in Fierce Biotech and as Holoclara advanced its lead candidate, HC002, into Phase 1 trials, press release here.
- Featured sessions at the Aspen Ideas: Health 2024 showcasing to the general public the scientific vision and impact of Holoclara’s approach
- Maintaining strong media relationships to ensure Holoclara’s future milestones continue to receive high-profile coverage.
Impact
Thermal’s strategic communications support has enabled Holoclara to:
-
- Own the narrative around worm-derived therapeutics, ensuring credibility and differentiation in a competitive biotech landscape.
- Secure investor and industry attention, with top-tier media placements that reinforced Holoclara’s potential to transform autoimmune disease treatment.
- Build lasting visibility as it advances through clinical development, ensuring continued recognition at the intersection of biotech and immunology.
Thermal continues to work with Holoclara, shaping its public narrative, amplifying key milestones, and ensuring its pioneering science reaches the right audiences.
“We are proud to bring a completely new type of medicine into the clinic — that harnesses molecules from worms, our natural partners who have co-evolved with humans and protected us from disease over millennia — and look forward to further progress on HC002 and our broader portfolio.”
Andrea Choe – CEO of Holoclara
